Clinical Medicine Reviews in Therapeutics 2012:4 109-122
Review
Published on 25 Jul 2012
DOI: 10.4137/CMRT.S3393
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Reviews in Therapeutics
Risedronate is a third generation bisphosphonate used in the prevention of osteoporotic fractures and the treatment of Paget’s disease. In patients with osteoporosis, risedronate reduces bone turnover, improves bone density and reduces the risk of both vertebral and non-vertebral fractures. Efficacy has been established in the treatment of postmenopausal osteoporosis, osteoporosis in men, and in osteoporosis secondary to glucocorticoids. There is a rapid onset of effect with a reduction in bone turnover seen within 1 month and fracture risk reduction as early as 6 months. In Pagets disease treatment with risedronate reduces bone turnover and improves bone pain. Short term treatment results in a sustained benefit.
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
Facebook Twitter
Pinterest